



CUOG

8th Annual CUA-CUOG Multidisciplinary GU Cancers Meeting 2023



Saturday, June 24, 2023



07:30 – 11:00 ET



**Le Centre Sheraton Montreal Hotel
Room: Salon ABC**

FINAL PROGRAM

MEETING CHAIRS



Peter Black

Senior Research Scientist, Vancouver Prostate Centre
Associate Director, Clinical Research, Vancouver Prostate Centre
Professor, Department of Urologic Sciences, University of British Columbia
Vice-President Education, Elect, Canadian Urological Association



Ricardo Rendon

Professor, Department of Urology
Director of Research and Clinical Trials, Dalhousie University
Chair, Genito-Urinary Cancer Site Team,
Nova Scotia Health Authority Cancer Program
Vice-President Education, Canadian Urological Association
Chair, Canadian Urologic Oncology Group

Learning Objectives:

At the conclusion of this meeting, attendees will be able to:

- Apply the most current evidence for selection and sequencing of systemic therapy options for patients with metastatic kidney cancer
- Integrate the use of PSMA-PET imaging in the management of patients with biochemical recurrence after local therapy of prostate cancer
- Understand the utility of biomarker testing to guide the use of PARP inhibitors in men with metastatic castrate-resistant prostate cancer
- Describe the impact of extended versus standard pelvic lymph node dissection on survival after radical cystectomy for muscle-invasive bladder cancer



This event is an Accredited Group Learning Activity (Section 1) as defined by the Maintenance of Certification Program of the Royal College of Physicians and Surgeons of Canada and approved by the Canadian Urological Association.

You may claim a maximum of 3 hours of credit.

MEETING EVALUATION FORM



AGENDA

07:00 - 07:30 CUOG Annual General Meeting (for CUOG members only)

07:30 - 08:00 Breakfast
CUA Prostate Pitch Presentations



08:00 - 08:05 Welcome & Introduction
[Ricardo Rendon](#)

BLADDER CANCER SESSION MODERATOR: PETER BLACK

08:05 - 08:20 State-of-the-Art Lecture
Mix and match: Optimal combination of systemic and local therapy for MIBC
[Thomas Powles](#)

08:20 - 08:40 Point/Counterpoint
Extended vs. standard pelvic lymph node dissection with radical cystectomy
◦ Pro-ePLND: [Andrea Kokorovic](#)
◦ Pro-sPLND: [Melissa Huynh](#)

08:40 - 08:55 Quality of life after radical cystectomy
[Bernie Bochner](#)

PROSTATE CANCER SESSION MODERATOR: ROB HAMILTON

08:55 - 09:15 State-of-the-Art Lecture
Real-time prostate pathology with Raman spectroscopy
[Miles Mannas](#)

09:15 - 09:45 Case-based Discussion
PSMA-PET for biochemical recurrence after local therapy
[Moderator: Rob Hamilton](#)
[Panel: Jean-Mathieu Beauregard, Urban Emmenegger, Cynthia Ménard, Frédéric Pouliot](#)

09:45 - 10:05 Point/Counterpoint
PARP inhibitors: Biomarker selected or all comers?
◦ Biomarker selected: [Eleni Efstathiou](#)
◦ All comers: [Kim Chi](#)

KIDNEY CANCER SESSION MODERATOR: RICARDO RENDON

10:05 - 10:20 State-of-the-Art Lecture
Refining RCC management through molecular imaging
[Patrick Richard](#)

10:20 - 10:40 Point/Counterpoint
Precision oncology and RCC: Fact or fiction?
◦ Fact: [Lori Wood](#)
◦ Fiction: [Alexis Rompré-Brodeur](#)

TESTIS CANCER SESSION MODERATOR: RICARDO RENDON

10:40 - 10:55 State-of-the-Art Lecture
Emerging role of miRNA to guide treatment in testis cancer
[Lucia Nappi](#)

10:55 - 11:00 Closing Remarks
[Peter Black](#)



Energy-elevating refreshments will
be served in the meeting room.

Thank you to our sponsors

FOUNDING SPONSORS



SUPPORTING SPONSORS

AMGEN PFIZER TOLMAR